Margarida F.
- Country
- Portugal
- Department
- Oncology
Research Overview
- Evaluation of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Stage III Unresectable Non-Small Cell Lung Cancer Post-Platinum-Based Chemoradiation
- Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab Monotherapy in PD-L1-high Metastatic Non-small Cell Lung Cancer
- Comparative Study of Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 and Pembrolizumab in Advanced/Metastatic Non-Squamous NSCLC
Data & Insights
Has run more than one trial at 26 of 179 partner sites.
Specializations
Lung Cancer Specialization
This investigator focuses on treating patients with non-small cell lung cancer (NSCLC), with particular emphasis on advanced and unresectable cases. Their expertise extends to managing Stage III NSCLC and evaluating novel therapeutic approaches.
- Advanced/metastatic non-squamous NSCLC
- Locally advanced unresectable NSCLC
- KRAS G12C mutation positive NSCLC
Their research encompasses both early-stage and metastatic disease states.
Innovative Therapies
The investigator specializes in evaluating targeted immunotherapy approaches for lung cancer treatment, including novel combinations of therapeutic agents. Their work involves assessment of biosimilar treatments and comparative effectiveness studies.
- Immunotherapy combinations
- Targeted molecular therapies
- Biosimilar development
Their research includes evaluation of both established and experimental therapeutic agents.
Treatment Modalities
The investigator's expertise includes the integration of concurrent chemoradiation therapy with other treatment approaches. They focus on developing therapeutic strategies for patients with specific genetic markers and varying disease stages.
- Combined modality treatments
- Mutation-specific therapies
- Sequential treatment approaches
Their work emphasizes personalized treatment approaches based on molecular profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.